Fw: [NVIC] SV-40 Linked to Blood Cancer

[Guest guest]

 

----

 

 

kathi

03/31/04 16:29:58

news

[NVIC] SV-40 Linked to Blood Cancer

 

E-NEWS FROM THE NATIONAL VACCINE INFORMATION CENTER

Vienna, Virginia http://www.nvic.org

 

* * * * * * * * * * * * * * * * * * * * * * *

UNITED WAY/COMBINED FEDERAL CAMPAIGN

#9119

* * * * * * * * * * * * * * * * * * * * * * *

 

"Protecting the health and informed consent rights of children since 1982."

 

==========================================================================================

 

http://www.eurekalert.org/pub_releases/2004-03/uotm-mvm032604.php

 

Public release date: 29-Mar-2004

 

 

Contact: Julie Penne

jpenne

713-792-0655

University of Texas M. D. Anderson Cancer Center

 

Monkey virus may hold clue for development of common blood cancer

 

ORLANDO -- Examination of tumors in patients with newly diagnosed

non-Hodgkin's lymphoma found that half of them show evidence of a monkey

virus DNA that may have originated from contaminated polio vaccines.

These findings suggest that Simian virus 40 (SV40) may "participate" in the

development of the blood cancer, say researchers from The University of

Texas M. D. Anderson Cancer Center, who presented their findings at the

annual meeting of the American Association for Cancer Research.

 

There is no known etiology for most non-Hodgkin's lymphoma, which has

doubled in incidence within the past 30 years, say the researchers.

 

"We found a strong association between the monkey virus DNA and

non-Hodgkin's lymphoma in this study, and now the question is whether the

virus DNA is there as an innocent bystander, or if it has a role to play in

causing the cancer," says the first author, Felipe Samaniego, M.D.,

assistant professor in the Department of Lymphoma/Myeloma.

 

There has been a debate as to whether SV40, which contaminated some batches

of polio vaccine in the 1950s and 60s, could cause human cancer, especially

after the virus was discovered in human tumors. Given that, the M. D.

Anderson researchers looked to see if either DNA from the virus or

associated antigens or antibodies could be found in non-Hodgkin's lymphoma.

 

One reason they looked for evidence of SV40 in non-Hodgkin's lymphoma is

because other viruses have been commonly found in this form of lymphoma,

including Epstein Barr virus. "The assumption has long been that if only

some NHL cases showed signs of virus, the rest may have another virus

involved in the development of this lymphoma," says Samaniego. "Now we

wonder, which one is most important?"

 

The research team, which included Suizhao Wang, M.D., Ph.D., and Shu Wang,

M.D., both post doctoral fellows in the Department of Lymphoma/Myeloma,

examined 55 tumors taken from patients newly diagnosed with the disease who

had not yet been treated with chemotherapy. After isolating DNA from the

genomes of the cancer cells, the researchers found that 33 of the tumors

contained DNA sequences from the anitigen produced by the virus. And 30 of

57 tumors stained positive with antibody that recognizes the large T antigen

of SV40.

 

There is no question that SV40 is a powerful cancer virus in some animals,

says Samaniego. In a hamster, for example, the virus causes both lymphomas

and mesotheolioma lung cancers, as well as tumors in the brain and bones.

 

People may pick up the virus by association with infected animals, through a

polio vaccine, or even though secretions, such as saliva, from a person

already infected, he says. One study suggested that at least five percent of

Americans have signs of infection with the monkey virus, says Samaniego.

 

But he theorizes that the body's immune system normally keeps the virus in

check until "a transforming event, inflammation or other disease," says

Samaniego. "Then the virus may reactivate and cause cancer."

 

If SV40 does prove to play a role in development of non-Hodgkin's lymphoma,

then treatment aimed at destroying the virus could help prevent its

development, he says. "The virus could serve as a target in novel

immune-based prevention and therapeutic strategies for non-Hodgkin's

lymphoma," Samaniego says. "Although this cancer is quite treatable with a

60 percent cure rate, a new therapeutic strategy would be welcomed."

 

 

=============================================

News is a free service of the National Vaccine Information

Center and is supported through membership donations. Learn more about vaccines, diseases and how to protect your informed

consent rights http://www.nvic.org

 

Become a member and support NVIC's work https://www.909shot.com/order.htm

 

To sign up for a free e-mail subscription http://www.nvic.org/emaillist.htm

 

To from this list, send an email to news-request and type

UNSUBSCRIBE in the body of the email.

 

NVIC is funded through individual membership donations and does not receive government funding. Barbara Loe Fisher, President and Co-founder.

NOTE: This is not an interactive e-mail list. Please do not respond to messages.